Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.43 --0%
EPS Growth %: +400.0%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
NSLR, OCTV, ACB, More
EPS Growth %: +400.0%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
NSLR, OCTV, ACB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $15.5 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brinker International (EAT) Misses Q4 EPS by 2c ; Offers Guidance
- Global-e Online (GLBE) Tops Q2 EPS by 16c ; Offers Guidance
- Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
